President Donald Trump released a healthcare policy framework Jan. 15 that raises many questions about its implementation and legislative viability.
The president’s proposal calls on Congress to codify voluntary drug pricing agreements with pharmaceutical companies, provide direct payments to Americans over extending enhanced ACA subsidies, and expand price transparency requirements for insurers and providers.
Five days later, a bipartisan group of lawmakers unveiled a healthcare deal tied to a broader government funding package. That proposal includes major wins for providers, including a multiyear delay of Medicaid disproportionate share hospital payment cuts, extensions of key Medicare payment programs for rural hospitals, permanent hospital-at-home authority, and telehealth flexibilities. However, the congressional deal notably omits the drug pricing agreements and direct payments preferred by President Trump, instead focusing on measures with broad bipartisan support. Lawmakers hope to pass it before a Jan. 30 deadline to avoid a partial government shutdown.
In statements shared with Becker’s about the president’s proposal, the Alliance of Community Health Plans said it looks forward “to learning more about the administration’s plans,” while AHIP said “health plans welcome ideas to bring down the unaffordable prices drugmakers charge Americans.”
David Merritt, the Blue Cross Blue Shield Association’s senior vice president of external affairs, said, “It is encouraging that President Trump’s plan includes a focus on the root causes driving up healthcare premiums, like drug prices.” AHIP also pointed to cost drivers like hospital consolidation and site-of-care pricing, which the administration’s plan doesn’t address.
Three big questions about President Trump’s healthcare policy proposal:
1. How would direct payments to Americans actually work, and what happens to enrollees on the ACA marketplace?
The Trump plan centers on eliminating direct ACA subsidy payments to insurers in favor of sending funds to eligible Americans to purchase their own coverage.
The proposal does not specify the mechanism for these payments or whether purchased plans would need to meet ACA standards, including preexisting condition protections.
President Trump and some congressional Republicans have previously supported replacing enhanced ACA subsidies with contributions to health savings accounts. In December, Sens. Mike Crapo, R-Idaho, and Bill Cassidy, R-La., proposed legislation that would provide an annual HSA contribution of $1,000 for individuals ages 18 to 49 or $1,500 for individuals ages 50 to 64. The legislation would have also funded cost-sharing reduction payments and allowed individual-market consumers to purchase catastrophic plans.
An HSA approach would face major barriers. HSA funds can’t currently be used to pay insurance premiums, and only those enrolled in eligible high-deductible health plans can make contributions. In 2023, 4% of HSA contributions nationally were made by people with incomes below $50,000, while 82% of marketplace enrollees had incomes below $46,950.
A White House official said Jan. 15 that consumers outside the ACA market would also qualify for direct payments, according to CNBC, though no additional details were provided.
The proposal comes as ACA premiums have surged for 2026 coverage. A December report from the Urban Institute found that marketplace benchmark premiums have increased by an average of 21.7%, driven by factors similar to those affecting employer-sponsored coverage, including higher provider wages, health system consolidation and growing use of GLP-1s, according to the Commonwealth Fund.
The Trump proposal also does not address whether purchased plans would need to meet ACA standards. Short-term, limited-duration health plans (also known as “junk” plans) could become an option if direct payments allow purchases outside ACA marketplaces. In August 2025, the Trump administration said it would not enforce Biden-era regulations on those types of plans.
Short-term plans can deny coverage for people with preexisting conditions, base premiums on member characteristics, avoid out-of-pocket maximums and skip federal essential health benefit requirements. These plans typically have lower premiums than unsubsidized Bronze-level ACA plans, and five states do not allow their sale.
2. What’s the legislative path forward, and does this kill bipartisan ACA subsidy talks?
The new proposal from the White House comes as a deal to extend the now-lapsed enhanced ACA subsidies has not come to fruition.
In the Senate, a bipartisan group’s draft legislation would create an HSA option in the second year of a two-year subsidy extension, though that proposal is not expected to be ready until the end of January. The House passed a three-year subsidy extension in early January, which has stalled in the Senate, and President Trump has hinted that he may veto any subsidy extension.
A White House official told CNBC on Jan. 15 that the healthcare plan does not mean the subsidies won’t be extended, but instead explains the president’s preferred policies.
Sen. Bernie Moreno, R-Ohio, who is leading the bipartisan negotiations on restoring the enhanced subsidies, said Jan. 15 that he “loved” the president’s healthcare plan, according to NPR, and that the exclusion of a subsidy extension didn’t disrupt those talks.
CMS Administrator Mehmet Oz, MD, declined to provide policy details Jan. 15, describing the proposal as a “broad framework” to NPR and referring reporters to a White House official. That official also avoided specifics but noted any future legislation wouldn’t replace other potential laws. Dr. Oz told The New York Times the plan addresses complaints about drug costs, insurance premiums beyond the ACA, and “the lack of accountability of big insurance.”
3. What’s the enforcement mechanism for any of this?
The enforcement details of President Trump’s framework also remain largely undefined. Unlike previous efforts — such as the most-favored-nation drug pricing model introduced during his first term, which was blocked in court — the current proposal does not lay out legal mechanisms to implement or defend similar pricing tools.
The plan also expands on price transparency rules, but offers no clear penalty structure or enforcement pathway. While CMS has fined hospitals for noncompliance, no insurers have faced penalties despite persistent data gaps. The framework does not specify whether new enforcement authorities would be created or how existing ones would be used. From a legislative standpoint, much of the proposal would likely require passage through regular order (needing 60 votes in the Senate) rather than through budget reconciliation, which only requires a simple majority.
National hospital groups largely see President Trump’s healthcare plan as “a framework of policy ideas” rather than a ready-for-vote package, noting that many of the provisions lack full Republican consensus and are not currently expected to move via reconciliation.
